ArticleDermatology reports2026

Targeting JAK/STAT signaling: ruxolitinib cream in the management of concurrent vitiligo and discoid lupus erythematosus.

Andrea Bassi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.